Mirvetuximab Soravtansine Completed Phase 3 Trials for Fallopian Tubes Cancer / Epithelial Ovarian Cancer / Primary Peritoneal Carcinoma / Ovarian Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02631876A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer